Page 50 - Use Authorization News Today

Criticized over its pandemic response, the government is planning legislation to accelerate approval

EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with

Share: EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with 400 patients to be enrolled into  Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 - DARPin ® DARPin ®  therapeutics well suited for a pandemic setting due to multi-specific target bi...

CytoSorbents to Present at the Jefferies Virtual Healthcare Conference News provided by Share this article Share this article MONMOUTH JUNCTION, N.J., May 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Companys progress and outlook at the Jef...

 E-Mail Houston Methodist announced today, in partnership with the U.S. Department of Health and Human Services (HHS), that it has expanded access to COVID-19 monoclonal antibody therapy (mAb) in the Greater Houston area. The promising treatment has been shown to keep high-risk COVID-19 patients out of the hospital and reduce the likelihood of progression to severe disease. Monoclonal antibodies are laboratory-made proteins that mimic the immune systems ability to fight off harmful pathogens s...

Novartis Pharma AG: Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 - DARPin antiviral therapeutic candidates that are undergoing testing to target SARS-CoV-2 spike protein DARPin therapeut...

ExThera Medical Corporation: Blood Purification and Pathogen Reduction Treatment for Sepsis and COVID-19 Set for Pan-European Distribution Launch ExThera Medicals Seraph 100 Microbind Affinity Filter (Seraph 100) is now being distributed in Europe by Fresenius Medical Care, the worlds leading provider of products and services for individuals with renal diseases. Since 2019 the therapeutic device has been used throughout the continent under a CE Mark for the treatment of bloodstream infections...

It's a definite maybe.

On May 17, 2021, Massachusetts Gov. Charles Baker announced that effective May 29, 2021 the Commonwealth will lift all remaining COVID-19 restrictions on businesses. In addition,...

QIAGEN receives U.S. FDA Emergency Use Authorization for fast and easy-to-use digital test to detect SARS-CoV-2 coronavirus antibodies Product News: QIAGEN receives U.S. FDA Emergency Use Authorization for fast and easy-to-use digital test to detect SARS-CoV-2 coronavirus antibodies 21 May 2021 QIAGEN has announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and easy-to-use QIAreach ® Anti-SARS-CoV-2 Total Test. The authorizat...